Author | Bruce Rubinger

Articles

Protecting IP Throughout the Product Lifecycle

August 01, 2003

Pharmaceutical Executive

Article

Now that patents on several blockbuster drugs have expired, the industry-feeling the pinch-has focused its attention on intellectual property. Because every additional month of market exclusivity can mean an extra $50 million or more in revenue, pharma companies have gone to great lengths to block the entry of generic competition.